Log in

Relevant bibliographies by topics / Kidney Cancer / Journal articles

To see the other types of publications on this topic, follow the link: Kidney Cancer.

Journal articles on the topic 'Kidney Cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Kidney Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Franjic, Sinisa. "A Few Words about Kidney Cancer." Clinical Case Reports and Trails 1, no. 1 (2022): 01–03. http://dx.doi.org/10.58489/2836-2217/001.

Full text

Abstract:

Kidney cancer is a malignant disease that affects a large number of adults around the world. The kidneys are paired organs, extremely important for the normal functioning of the body. Each person has two kidneys, left and right, located along the spine and below the ribs. The kidneys are the main filters in the human body and perform multiple functions. They are responsible for fluid control, excretion of toxins, mineral salts, production of the hormone erythropoietin which stimulates the production of red blood cells. Each kidney works independently and a person can live with one kidney. When

APA, Harvard, Vancouver, ISO, and other styles

2

Nasir, Muhammad Umar, Muhammad Zubair, Taher M. Ghazal, et al. "Kidney Cancer Prediction Empowered with Blockchain Security Using Transfer Learning." Sensors 22, no. 19 (2022): 7483. http://dx.doi.org/10.3390/s22197483.

Full text

Abstract:

Kidney cancer is a very dangerous and lethal cancerous disease caused by kidney tumors or by genetic renal disease, and very few patients survive because there is no method for early prediction of kidney cancer. Early prediction of kidney cancer helps doctors start proper therapy and treatment for the patients, preventing kidney tumors and renal transplantation. With the adaptation of artificial intelligence, automated tools empowered with different deep learning and machine learning algorithms can predict cancers. In this study, the proposed model used the Internet of Medical Things (IoMT)-ba

APA, Harvard, Vancouver, ISO, and other styles

3

Rambe, Tri Putra Rahmad Ramadani, and M. Hidayat Surya Atmaja. "Kidney cancer with complications in Dr. Soetomo Regional Public Hospital, Surabaya, Indonesia." International journal of health sciences 6, S1 (2022): 1832–41. http://dx.doi.org/10.53730/ijhs.v6ns1.4944.

Full text

Abstract:

Kidney cancer is a disease in which kidney cells become malignant and grow uncontrollably, forming a mass or tumor. Before discussing further kidney cancer, it is important to briefly know the kidneys. The kidneys are two bean-shaped organs located in the lower abdomen on the left and right of the spine. The primary function of the kidneys is to excrete and excrete water, salt, and other unnecessary substances and turn them into urine. The urine collects in the renal pelvis (the funnel-shaped part of each kidney), then travels to the ureters (the tube between the kidneys and bladder), and fina

APA, Harvard, Vancouver, ISO, and other styles

4

Graham, Jeffrey. "ASCO GU22 – Kidney Cancer Highlights." Kidney Cancer Journal 20, no. 1 (2022): 32–33. http://dx.doi.org/10.52733/kcj20n1-gu2.

Full text

Abstract:

The 2022 ASCO Genitourinary Cancers Symposium took place in San Francisco between February 17-19th. As always, the scientific program contained several exciting abstracts with a focus on prostate cancer, bladder cancer, and kidney cancer. Here we will highlight key abstracts related to kidney cancer/renal cell carcinoma presented at this year’s symposium.

APA, Harvard, Vancouver, ISO, and other styles

5

Hasumi, Hisashi, Masaya Baba, Yukiko Hasumi, et al. "Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn." Proceedings of the National Academy of Sciences 112, no. 13 (2015): E1624—E1631. http://dx.doi.org/10.1073/pnas.1419502112.

Full text

Abstract:

Folliculin (FLCN)-interacting proteins 1 and 2 (FNIP1, FNIP2) are homologous binding partners of FLCN, a tumor suppressor for kidney cancer. Recent studies have revealed potential functions for Flcn in kidney; however, kidney-specific functions for Fnip1 and Fnip2 are unknown. Here we demonstrate that Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. We observed no detectable phenotype in Fnip2 knockout mice, whereas Fnip1 deficiency produced phenotypes similar to those seen in Flcn-deficient mice in multiple organs, but not in kidneys. We found that abs

APA, Harvard, Vancouver, ISO, and other styles

6

Dean, Erin. "Kidney cancer." Cancer Nursing Practice 16, no. 8 (2017): 11. http://dx.doi.org/10.7748/cnp.16.8.11.s12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

_, _. "Kidney Cancer." Journal of the National Comprehensive Cancer Network 4, no. 10 (2006): 1072. http://dx.doi.org/10.6004/jnccn.2006.0089.

Full text

Abstract:

An estimated 38,890 Americans will be diagnosed with kidney cancer and 12,840 will die of this disease in the United States in 2006. Renal cell carcinoma (RCC) constitutes approximately 2% of all malignancies, with a median age at diagnosis of 65 years. Smoking and obesity are among the risk factors for RCC development, and tumor grade, local extent of the tumor, presence of regional nodal metastases, and evidence of metastatic disease at presentation are the most important prognostic determinants of 5-year survival. These guidelines discuss evaluation, staging, treatment, and management after

APA, Harvard, Vancouver, ISO, and other styles

8

Motzer, Robert J., Neeraj Agarwal, Clair Beard, et al. "Kidney Cancer." Journal of the National Comprehensive Cancer Network 7, no. 6 (2009): 618–30. http://dx.doi.org/10.6004/jnccn.2009.0043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Motzer, Robert J., Neeraj Agarwal, Clair Beard, et al. "Kidney Cancer." Journal of the National Comprehensive Cancer Network 9, no. 9 (2011): 960–77. http://dx.doi.org/10.6004/jnccn.2011.0082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Owens, Brian. "Kidney cancer." Nature 537, no. 7620 (2016): S97. http://dx.doi.org/10.1038/537s97a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Laino, Charlene. "Kidney Cancer." Oncology Times 30, no. 8 (2008): 16–18. http://dx.doi.org/10.1097/01.cot.0000319616.21951.54.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

DiGiulio, Sarah. "Kidney Cancer." Oncology Times 34, no. 10 (2012): 12–14. http://dx.doi.org/10.1097/01.cot.0000415254.40472.f9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

DiGiulio, Sarah. "Kidney cancer." Oncology Times UK 9, no. 6 (2012): 17. http://dx.doi.org/10.1097/01.otu.0000415649.34364.a9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Vogelzang, Nicholas J., and Walter M. Stadler. "Kidney cancer." Lancet 352, no. 9141 (1998): 1691–96. http://dx.doi.org/10.1016/s0140-6736(98)01041-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

DiGiulio, Sarah. "Kidney Cancer." Nephrology Times 5, no. 5 (2012): 13–14. http://dx.doi.org/10.1097/01.nep.0000415389.49208.c3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wallen, Eric M., Raj S. Pruthi, Geoffrey F. Joyce, and Matthew Wise. "Kidney Cancer." Journal of Urology 177, no. 6 (2007): 2006–19. http://dx.doi.org/10.1016/j.juro.2007.01.126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Chowdhury, Nivedita, and Charles G. Drake. "Kidney Cancer." Urologic Clinics of North America 47, no. 4 (2020): 419–31. http://dx.doi.org/10.1016/j.ucl.2020.07.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Linehan, W. Marston, and W. Kimryn Rathmell. "Kidney cancer." Urologic Oncology: Seminars and Original Investigations 30, no. 6 (2012): 948–51. http://dx.doi.org/10.1016/j.urolonc.2012.08.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

LaFollette, Sandra S. "Kidney Cancer." AORN Journal 56, no. 1 (1992): 31–48. http://dx.doi.org/10.1016/s0001-2092(07)66647-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Halperin, Edward C. "Kidney cancer." Lancet 353, no. 9152 (1999): 594. http://dx.doi.org/10.1016/s0140-6736(05)75656-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Johansson, Martin E., and Håkan Axelson. "Kidney cancer." Seminars in Cancer Biology 23, no. 1 (2013): 1–2. http://dx.doi.org/10.1016/j.semcancer.2012.05.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Hancock, S. Brandon, and Christos S. Georgiades. "Kidney Cancer." Cancer Journal 22, no. 6 (2016): 387–92. http://dx.doi.org/10.1097/ppo.0000000000000225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Torpy, Janet M. "Kidney Cancer." JAMA 292, no. 1 (2004): 134. http://dx.doi.org/10.1001/jama.292.1.134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Forum, Canadian Kidney Cancer. "Management of Kidney Cancer: Canadian Kidney Cancer Forum." Canadian Urological Association Journal 6, no. 1 (2013): 16. http://dx.doi.org/10.5489/cuaj.367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Miss., Surbhi Markam. "Tumors of Kidney." International Journal of Trend in Scientific Research and Development 3, no. 2 (2019): 663–71. https://doi.org/10.31142/ijtsrd21438.

Full text

Abstract:

Kidney tumors, also known as renal tumors, are tumors, or growths, on or in the kidney. These growths can be benign or malignant cancerous . They may be discovered on medical imaging incidentally i.e. anincidentaloma , or may be present in patients as an abdominal mass, hematuria, abdominal pain, or manifest first in aparaneoplastic syndrome that seems unrelated to the kidney. The most common form of kidney cancer in adults is renal cell carcinoma. Renal cell carcinoma usually does not cause obvious symptoms, especially in the early stages. As a result, the cancer may not be discovered until i

APA, Harvard, Vancouver, ISO, and other styles

26

Zheng, Guoqiao, Kristina Sundquist, Jan Sundquist, et al. "Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers." EUROPEAN UROLOGY OPEN SCIENCE 24, February 2021 (2021): 52–59. https://doi.org/10.1016/j.euros.2020.12.007.

Full text

Abstract:

Background: Second primary cancers (SPCs) are increasing due to improving survival in first primary cancers. Previous studies on SPCs in renal cell carcinoma (RCC) have focused on treatment and other risk factors, but data of RCC as an SPC are scarce. Objective: In this study, we want to elucidate the risk for any SPC after RCC, and in reverse order, for RCC as an SPC after any cancer. We additionally consider how family histories influence the risks. Design, setting, and participants: Patient data were obtained from the Swedish Cancer Registry from years 1990 through 2015, and family data wer

APA, Harvard, Vancouver, ISO, and other styles

27

Blitzer, Grace, Susan Tsai, Mohammed Aldakkak, et al. "Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?" Journal of Clinical Oncology 35, no. 4_suppl (2017): 442. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.442.

Full text

Abstract:

442 Background: Upper abdominal irradiation for pancreas cancer is given in close proximity to the radiation sensitive kidneys. While contemporary 3D and intensity modulated radiation therapy (IMRT) can decrease the total dose of radiation delivered to the kidneys; these plans may potentially exceed the established kidney dose constraints, especially if one kidney is providing most of the renal function. Less than 10% of the general population is estimated to have asymmetrical kidney function. Functional kidney scans using MAG3 clearance can give information about the contribution of each kidn

APA, Harvard, Vancouver, ISO, and other styles

28

Yuk, Hyeong-Dong, Kyoung-Hwa Lee, Hye-Sun Lee, et al. "PDLIM2 Suppression Inhibit Proliferation and Metastasis in Kidney Cancer." Cancers 13, no. 12 (2021): 2991. http://dx.doi.org/10.3390/cancers13122991.

Full text

Abstract:

We evaluated the expression of PDLIM2 in human kidney cancer cell lines from primary or metastatic origins and found that PDLIM2 expression was highly elevated in metastatic kidney cancers. We evaluated the effect of PDLIM2 inhibition by RNA interference method. PDLIM2 knockdown showed the decreased proliferation and metastatic character in human metastatic kidney cancer cells. By repeated round of orthotopic injection of RenCa mouse kidney cancer cell line, we obtained metastatic prone mouse kidney cancer cell lines. PDLIM2 expression was highly expressed in these metastatic prone cells compa

APA, Harvard, Vancouver, ISO, and other styles

29

Burnasheva, E. V., Y. V. Shatokhin, I. V. Snezhko, and A. A. Matsuga. "KIDNEY INJURY IN CANCER THERAPY." Nephrology (Saint-Petersburg) 22, no. 5 (2018): 17–24. http://dx.doi.org/10.24884/1561-6274-2018-22-5-17-24.

Full text

Abstract:

Кidney injury is a frequent and significant complication of cancer and cancer therapy. The kidneys are susceptible to injury from malignant infiltration, damage by metabolites of malignant cells, glomerular injury, nephrotoxic drugs including chemotherapeutic agents. Also bone marrow transplantation complications, infections with immune suppression (including septicemia), tumor lysis syndrome should be taken into account. Chemotherapeutic agents are a common cause of acute kidney injury but can potentially lead to chronic kidney disease development in cancer patients. This article summarizes r

APA, Harvard, Vancouver, ISO, and other styles

30

Wang, Yichen, Sarah Moody, Behnoush Abedi-Ardekani, et al. "Abstract 1168: Mutational processes in tumour-adjacent normal kidneys across countries with varying cancer incidence rates." Cancer Research 83, no. 7_Supplement (2023): 1168. http://dx.doi.org/10.1158/1538-7445.am2023-1168.

Full text

Abstract:

Abstract In recent years, large-scale whole genome sequencing of multiple types of cancer across multiple continents has been conducted as part of the “Mutographs” Cancer Grand Challenge to uncover unknown causes of cancer through detection of signatures of mutational processes operative during cancer development. Distinct mutational signatures have recently been detected by “Mutographs” in Renal Clear Cell Carcinomas (RCC) from different parts of the world. However, whether the detected mutational signatures are present in normal tissues or are initiated after tumorigenesis remains unknown. I

APA, Harvard, Vancouver, ISO, and other styles

31

Peired, Anna Julie, Elena Lazzeri, Francesco Guzzi, Hans-Joachim Anders, and Paola Romagnani. "From kidney injury to kidney cancer." Kidney International 100, no. 1 (2021): 55–66. http://dx.doi.org/10.1016/j.kint.2021.03.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Lee, Kyoung-Hwa, Byung-Chan Kim, Seung-Hwan Jeong, et al. "Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity." International Journal of Molecular Sciences 21, no. 17 (2020): 6089. http://dx.doi.org/10.3390/ijms21176089.

Full text

Abstract:

Kidney cancer is one of the most difficult cancers to treat by targeted and radiation therapy. Therefore, identifying key regulators in this cancer is especially important for finding new drugs. We focused on androgen receptor (AR) regulation by its epigenetic co-regulator lysine-specific histone demethylase 1 (LSD1) in kidney cancer development. LSD1 knock-down in kidney cancer cells decreased expression of AR target genes. Moreover, the binding of AR to target gene promoters was reduced and histone methylation status was changed in LSD1 knock-down kidney cancer cells. LSD1 knock-down also sl

APA, Harvard, Vancouver, ISO, and other styles

33

Duha, Diki Arma, Edward Usfie Harahap, Rachmat Budi Santoso, and Ikhlas Arief Bramono. "Kidney Cancer Profile in National Cancer Center (NCC) - Dharmais Cancer Hospital." Indonesian Journal of Cancer 16, no. 4 (2022): 226. http://dx.doi.org/10.33371/ijoc.v16i4.904.

Full text

Abstract:

Background: Kidney cancer is one of the most prevalent cancers in urology. The higher prevalence of risk factors, as well as better diagnostic modalities, has led to a reported increase worldwide. The study aims to describe the profile and management pattern of kidney cancer patients at a tertiary referral center over seven years.Methods: A descriptive study was conducted to assess the profile and management of kidney patients in the national cancer center (NCC) - Dharmais Hospital Jakarta between January 2013 and December 2020. The variables collected included age, gender, stage (AJCC staging

APA, Harvard, Vancouver, ISO, and other styles

34

Rasmussen, Robert, Thomas Sanford, Anil V. Parwani, and Ivan Pedrosa. "Artificial Intelligence in Kidney Cancer." American Society of Clinical Oncology Educational Book, no. 42 (April 2022): 1–11. http://dx.doi.org/10.1200/edbk_350862.

Full text

Abstract:

Artificial intelligence is rapidly expanding into nearly all facets of life, particularly within the field of medicine. The diagnosis, characterization, management, and treatment of kidney cancer is ripe with areas for improvement that may be met with the promises of artificial intelligence. Here, we explore the impact of current research work in artificial intelligence for clinicians caring for patients with renal cancer, with a focus on the perspectives of radiologists, pathologists, and urologists. Promising preliminary results indicate that artificial intelligence may assist in the diagnos

APA, Harvard, Vancouver, ISO, and other styles

35

Buchberger, David, Paul Kreinbrink, and Jordan Kharofa. "Proton Therapy in the Treatment of Anal Cancer in Pelvic Kidney Transplant Recipients: A Case Series." International Journal of Particle Therapy 6, no. 1 (2019): 28–34. http://dx.doi.org/10.14338/ijpt-19-00067.1.

Full text

Abstract:

Abstract Purpose: The incidence of anal cancer in patients with kidney transplants has increased. The definitive treatment for anal cancer is chemotherapy and intensity-modulated radiation therapy. In kidney transplant recipients, sparing the pelvic kidney in the process of delivering radiation to the anus can be challenging. Intensity-modulated proton therapy (IMPT) has been proposed as an alternative to intensity-modulated radiation therapy for the treatment of anal cancer in this population, given its increased ability to spare organs-at-risk. Case Series: We present 4 cases of patients wit

APA, Harvard, Vancouver, ISO, and other styles

36

Muscella, Antonella, Leonardo Resta, Luca Giulio Cossa, and Santo Marsigliante. "Immunolocalization of the AT-1R Ang II Receptor in Human Kidney Cancer." Biomolecules 13, no. 8 (2023): 1181. http://dx.doi.org/10.3390/biom13081181.

Full text

Abstract:

This study aimed to evaluate AT1-R expression in normal and cancerous human kidneys, how these expressions are modified, and AT1-R functionality. AT-1R mRNA expression, determined by real-time PCR, was detected in all samples. AT-1R mRNA increased in well-differentiated cancer (G1, p < 0.01) and decreased 2.9-fold in undifferentiated cancer (G4, p < 0.001) compared with normal kidney tissues. Immunocytochemistry analysis showed that the AT-1R was expressed in the normal tubular epithelium. The glomerulus was also immunoreactive, and as expected, the smooth muscle cells of the vessel wall

APA, Harvard, Vancouver, ISO, and other styles

37

Goodman, Alice. "Advanced Kidney Cancer." Oncology Times 29, no. 12 (2007): 8. http://dx.doi.org/10.1097/01.cot.0000282580.73692.0c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Fromer, Margot J. "Metastatic Kidney Cancer." Oncology Times 27, no. 3 (2005): 16. http://dx.doi.org/10.1097/01.cot.0000288813.54319.2c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Dixon, Carl F. "Kidney Cancer Association." Oncology Times 24, no. 9 (2002): 4. http://dx.doi.org/10.1097/01.cot.0000289199.30118.78.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Kelley, Celeste. "Kidney Cancer Association." Neoplasia 4, no. 5 (2002): 464. http://dx.doi.org/10.1038/sj.neo.7900261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Yuan, Yan, Guillermo Marshall, Catterina Ferreccio, et al. "Kidney Cancer Mortality." Epidemiology 21, no. 1 (2010): 103–8. http://dx.doi.org/10.1097/ede.0b013e3181c21e46.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Libertino, John A. "Editorial: Kidney Cancer." Journal of Urology 155, no. 2 (1996): 466–67. http://dx.doi.org/10.1016/s0022-5347(01)66419-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Fromer, Margot J. "Metastatic kidney cancer." Oncology Times 2, no. 4 (2005): 6–8. http://dx.doi.org/10.1097/01434893-200504000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hwang, Jonathan J., Edward M. Uchio, W. Marston Linehan, and McClellan M. Walther. "Hereditary kidney cancer." Urologic Clinics of North America 30, no. 4 (2003): 831–42. http://dx.doi.org/10.1016/s0094-0143(03)00054-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Alekseev, B. Ya, A. S. Kalpinsky, N. V. Vorobyev, K. M. Nyushko, K. Yu Kanukoev, and A. D. Kaprin. "Bilateral kidney cancer." Onkologiya. Zhurnal imeni P.A.Gertsena 5, no. 1 (2016): 55. http://dx.doi.org/10.17116/onkolog20165155-62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Linehan, W. Marston, Peter A. Pinto, Gennady Bratslavsky, et al. "Hereditary kidney cancer." Cancer 115, S10 (2009): 2252–61. http://dx.doi.org/10.1002/cncr.24230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Forum, Canadian Kidney Cancer. "Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update." Canadian Urological Association Journal 3, no. 3 (2013): 200. http://dx.doi.org/10.5489/cuaj.1069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Jewett, Michael A. S., J. J. Knox, and C. Kollmannsberger. "Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement." Canadian Urological Association Journal 2, no. 3 (2013): 175. http://dx.doi.org/10.5489/cuaj.567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Tichanek, Filip, Asta Försti, Akseli Hemminki, Otto Hemminki, and Kari Hemminki. "Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century." Cancers 15, no. 10 (2023): 2782. http://dx.doi.org/10.3390/cancers15102782.

Full text

Abstract:

Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971–2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016–2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-ye

APA, Harvard, Vancouver, ISO, and other styles

50

SeokShin, Hong, Hyun JinJung, and Jae ShinPark. "Bladder cancer presenting as a retroperitoneal urinoma of kidney." International Journal of Medical Reviews and Case Reports 2, Reports in Surgery and Dermatolo (2018): 1. http://dx.doi.org/10.5455/ijmrcr.retroperitoneal-urinoma-kidney.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!